Catalyst Pharmaceuticals (Nasdaq:CPRX) - Cotización, noticias y análisis

Resumen de acción CPRX

Catalyst Pharmaceuticals, Inc. es una empresa biofarmacéutica en fase comercial centrada en el desarrollo y la comercialización de terapias para personas con enfermedades neuromusculares y neurológicas raras, debilitantes y crónicas en Estados Unidos.

Acerca de la empresa

CPRX análisis fundamental
Puntuación del copo de nieve
Valoración	4/6
Crecimiento futuro	5/6
Resultados anteriores	2/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Cotiza un 72.7% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 20%

Los analistas coinciden en que el precio de las acciones subirá un 82.3%

Análisis de riesgos

Los accionistas han sido diluidos en el último año

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Los márgenes de beneficio (15.8%) son inferiores a los del año pasado (38.8%)

Competidores de Catalyst Pharmaceuticals, Inc.

MannKind

NasdaqGM:MNKD

US$1.4b

ADMA Biologics

NasdaqGM:ADMA

US$4.0b

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.6b

Protagonist Therapeutics

NasdaqGM:PTGX

US$2.4b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Catalyst Pharmaceuticals
Precios históricos de las acciones
Precio actual de la acción	US$19.24
Máximo en 52 semanas	US$19.86
Mínimo de 52 semanas	US$11.55
Beta	0.70
11 mes Cambio	14.87%
Variación en 3 meses	17.32%
Cambio de 1 año	30.53%
3Variación en 3 años	239.33%
Variación en 5 años	206.86%
Variación desde la OPV	215.41%

Noticias y actualizaciones recientes

Recent updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

Rentabilidad de los accionistas

	CPRX	US Biotechs	Mercado US
7D	18.5%	3.8%	4.5%
1Y	30.5%	12.6%	21.7%

Rentabilidad vs. Industria: CPRX superó a la industria US Biotechs, que obtuvo un rendimiento del 13.1% el año pasado.

Rentabilidad vs. Mercado: CPRX superó al mercado US, que obtuvo un rendimiento del 14.1% el año pasado.

Volatilidad de los precios

Is CPRX's price volatile compared to industry and market?
CPRX volatility
CPRX Average Weekly Movement	5.9%
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Precio estable de las acciones: CPRX no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CPRX (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2002	167	Rich Daly	www.catalystpharma.com

Catalyst Pharmaceuticals, Inc, empresa biofarmacéutica en fase comercial, se centra en el desarrollo y la comercialización de terapias para personas con enfermedades neuromusculares y neurológicas raras, debilitantes y crónicas en Estados Unidos. Ofrece Firdapse, comprimidos de fosfato de amifampridina para el tratamiento de pacientes con síndrome miasténico de Lambert-Eaton (LEMS); y Ruzurgi para el tratamiento de pacientes pediátricos con LEMS. La empresa desarrolla Firdapse para el tratamiento de la miastenia gravis positiva a anticuerpos MuSK y la atrofia muscular espinal tipo.

Resumen de fundamentos de Catalyst Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Catalyst Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de CPRX
Capitalización bursátil	US$2.33b
Beneficios(TTM)	US$68.15m
Ingresos (TTM)	US$434.48m

33.5x

Ratio precio-beneficio (PE)

5.3x

Ratio precio-ventas (PS)

¿Está CPRX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CPRX
Ingresos	US$434.48m
Coste de los ingresos	US$151.27m
Beneficio bruto	US$283.20m
Otros gastos	US$215.05m
Beneficios	US$68.15m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.57
Margen bruto	65.18%
Margen de beneficio neto	15.69%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado CPRX a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción CPRX

Recompensas

Análisis de riesgos

Competidores de Catalyst Pharmaceuticals, Inc.

NasdaqGM:MNKD

US$1.4b

NasdaqGM:ADMA

US$4.0b

NasdaqGS:ACAD

US$2.6b

NasdaqGM:PTGX

US$2.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Recent updates

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock